Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio (NASDAQ: TELA) announced on November 3, 2025 the appointment of William “Bill” Plovanic, CFA, to its Board of Directors.

Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity and previously held C‑level operating and board roles at Obalon Therapeutics from 2016 to 2021. The company said his combination of capital markets expertise and hands‑on med‑tech operating experience will support corporate strategy and commercial execution as TELA Bio continues to develop soft‑tissue reconstruction solutions.

TELA Bio (NASDAQ: TELA) announced on October 9, 2025 the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors and the departure of director Lisa Colleran after five years of service.

Dr. Rocchio is Executive Vice President and Chief Nurse Executive at Advocate Health, overseeing more than 42,000 nurses and leading enterprise nursing strategy across a six-state system; the company highlighted her expertise in group purchasing organizations and supply-chain alignment. Ms. Colleran, CEO of IC Surgical and former CEO of LifeCell, stepped down after contributing commercial leadership since 2020.

TELA Bio (NASDAQ:TELA) reported strong Q2 2025 financial results with revenue of $20.2 million, representing 26% year-over-year growth and 9% sequential growth. The company's OviTex and OviTex PRS products saw significant demand increases, with year-over-year revenue growth of 12% and 53% respectively.

The company appointed Jeffrey Blizard as President to strengthen commercial leadership and announced the European launch of OviTex Inguinal for robotic procedures. Despite a gross profit of $14.1 million (69.8% margin), TELA Bio recorded a net loss of $9.9 million, an improvement from the $12.6 million loss in Q2 2024.

TELA Bio reiterated its full-year 2025 revenue guidance of $85.0-88.0 million, projecting 23-27% growth. The company ended Q2 with $35.0 million in cash and cash equivalents.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants to fourteen new employees. The Compensation Committee approved restricted stock units covering 10,200 shares of common stock, granted on August 5, 2025.

These grants, made under Nasdaq Rule 5635(c)(4), are part of the employees' compensation packages and will vest equally over four years, contingent on continued employment with TELA Bio.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on August 13th, 2025, at 10:00 am ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.

TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management's discussion of financial results and a corporate update. Interested investors must register in advance or at least 15 minutes before the call. The webcast and replay will be accessible through the Events & Presentations section of TELA's investor website.

TELA Bio announced the approval of inducement grants for Jim Hagen, the company's new Senior Vice President of Strategic Commercial Operations. The compensation package includes options to purchase 75,000 shares of common stock at $1.42 per share and restricted stock units covering 30,000 shares. The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over 36 months. The restricted stock units will vest in equal annual installments over four years. These equity awards were granted under Nasdaq Rule 5635(c)(4) as part of Hagen's employment compensation package.

TELA Bio (NASDAQ: TELA) has announced the European launch of OviTex Inguinal Reinforced Tissue Matrix, designed specifically for laparoscopic and robotic-assisted inguinal hernia repair. This launch follows its successful U.S. introduction in 2024, where it generated over $1 million in first-year sales. The product is available in two configurations (three- or four-layer anatomically shaped) and builds on the existing OviTex portfolio, utilizing ovine rumen with minimal polymer content. OviTex has demonstrated strong clinical efficacy with over 69,000 implantations and 40+ published works over 8 years. A notable retrospective study of 259 patients showed a low 1.2% recurrence rate with an average 1.5-year follow-up. The product will be showcased at the European Hernia Society Annual Congress in Paris.

TELA Bio has appointed Jeffrey Blizard as President, effective immediately. Blizard, who has served on TELA Bio's Board of Directors for the past year, joins from Abiomed (a Johnson & Johnson company) where he was Global Head of Surgical Sales. His appointment strengthens TELA Bio's executive leadership team as the medical technology company enters its next growth phase. Blizard brings significant industry experience from leading medtech companies including Medtronic, Intuitive Surgical, and Boston Scientific. Under his leadership at Abiomed, the Surgical Division experienced substantial growth. CEO Antony Koblish expressed confidence that Blizard's proven track record in scaling businesses and team leadership will enhance TELA Bio's market competitiveness and drive commercial performance.